abstract |
An antibody comprising two modifications with respect to a wild-type human Fc region, wherein said modifications are 428L and 434S, wherein said antibody has a longer half-life in a mammal compared to an antibody without said modifications, and wherein the numbering is in accordance with the EU index in Kabat et al., for use as a medicine. |